Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • who_gnu_1235 who_gnu_1235 May 4, 2014 9:54 AM Flag

    Timing Question

    Doing DD - Ganetespib may have huge potential in a variety of cancers, but drug trials are in early stages except Galaxy 2 P3 trial with results in 2016. In the interim it looks like it has 1 yrs worth of cash at current burn rate may require secondaries for several years. So my question is - what will make it pop short term and when? Eg - what do we expect on the May 8th CC?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The I-spy2 trial for breast cancer is a major coup. not only does it endeavor to speed the use of effective cancer drugs, it will also save lots of $$ for snta. Google and see for your self and I include quote below...

      ". I-SPY 2 was initiated as a pre-competitive consortium that brings together the Food and Drug Administration (FDA), National Cancer Institute (NCI), pharmaceutical companies, leading academic medical centers, and patient advocacy groups under its umbrella.

      “I-SPY 2 is an innovative study designed to accelerate the testing of promising investigational agents,” said Dr. Esserman, “Ganetespib has several important advantages that led to its selection for the I-SPY program: demonstrated single agent clinical activity, favorable safety profile, strong scientific rationale for use in breast cancer, and results in lung cancer showing improvement in outcomes when added to a taxane. The latter is particularly relevant for neo-adjuvant breast cancer, where taxane use is standard of care. The entire I-SPY TRIAL team is excited to participate in the evaluation of this agent and determine whether this agent will improve upon our current neoadjuvant therapy for women with aggressive breast cancer.”

 
SNTA
2.19-0.03(-1.35%)May 27 4:00 PMEDT